Abstract
Although definite curative therapy for metastatic breast cancer is lacking, a variety of therapies are used in an attempt to retard the progression of disease, ameliorate symptoms, and improve the quality and duration of survival time. In addition to the well-defined improvements in the supportive care of patients with metastatic breast cancer, a variety of new therapeutic agents with favorable therapeutic ratios have recently become available. These agents include hormonal, chemotherapeutic, and monoclonal antibody therapies. How best to incorporate these new strategies into the current management of patients is currently the focus of intensive preclinical and clinic research. Several recently completed and ongoing clinical trials promise to define the role of these new treatments in the management of metastatic breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 289-295 |
Number of pages | 7 |
Journal | Cancer Research Therapy and Control |
Volume | 9 |
Issue number | 3-4 |
State | Published - 1999 |
Keywords
- Chemotherapy
- Hormonal therapy
- Monoclonal antibody
ASJC Scopus subject areas
- Oncology
- Cancer Research